Australia’s ResApp partners in corporate health management

Digital & Innovation: ResApp Health, a Brisbane-based digital health company developing smartphone applications for the diagnosis and management of respiratory disease, signed a licensing agreement with Workplace Medicine Australia (WMA) to integrate ResApp’s acute respiratory diagnostic test ResAppDx in WMA’s corporate health and wellbeing management application, Medetective.

ResAppDx uses machine-learning (ML) technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone’s built-in microphone. It is CE Marked in Europe and TGA approved in Australia.

WMA will integrate ResAppDx into its new Medetective app, for use as a remote respiratory diagnostic aid alongside a telehealth consultation, reducing the need for employees to book in and travel to see a clinician for diagnosis. ResAppDx will be made available through telehealth medical consultations.

WMA provides holistic medical screening and consultation services for corporate clients across a range of different industries including financial services, insurance, mining and construction.

You may also like Healthscope adopts AI technology to enhance patient experience

CEO and Managing Director Dr Tony Keating said “As the adoption of telehealth continues in Australia, ResApp is witnessing increased interest in its software solutions. The company will look to capitalise on this in the near term, further diversifying its partnerships across industries to create a solid foundation for growth.

“This agreement with WMA is very important, as it considerably broadens the company’s visibility into new, large sectors with substantial workforces. We are confident that ResAppDx will greatly assist in the diagnosis of respiratory disease, before it becomes an issue in workplaces.”

Medical Director and Co-Founder of WMA Dr Scott Allison said “WMA has medical and engineering capabilities to allow its clients to better assess and manage risk as well as maintain a healthy workforce. With the future workplace continually adapting to drive and embrace a health focused culture, we have developed our Medetective platform to facilitate on-demand preventative medical support for organisations, informed by an array of remote medical diagnostic tools. ResAppDx will enable our clinicians to better assess respiratory symptoms when diagnosing patients remotely through our world-first, holistic health management platform,
Medetective.”

ResAppDx will now be integrated into the Medetective application, which is set to launch in February 2021. The two-year licence will commence from the launch date. Under the agreement, ResApp will receive a monthly fee for every worker that WMA’s gold or platinum service covers at a client workplace.

While revenue from the agreement cannot be estimated at this early stage
and is dependent on the number of clients signing up to WMA’s gold and platinum pricing tiers, ResApp remains confident of significant commercial uptake. The licence agreement may be extended beyond the initial two-year term by mutual agreement.